SEC Form 4 · accession 0001562180-18-002166
BIO-TECHNE Corp · TECH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kim Kelderman
Officer — President, Diagnostics & Genom
Period of report
May 1, 2018
Accepted (ET)
May 3, 2018 · 4:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000842023
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted StockF1,F2 | — | May 1, 2018 | A | 5,000 | A | — | May 1, 2025 | Common Stock | 5,000 | 5,000 | D |
| Stock Option (Right to Buy)F3 | $150.78 | May 1, 2018 | A | 2,652 | A | — | May 1, 2025 | Common Stock | 2,652 | 2,652 | D |
| Stock Option (Right to Buy)F4 | $150.78 | May 1, 2018 | A | 7,348 | A | — | May 1, 2025 | Common Stock | 7,348 | 10,000 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F2Vests 1,667 on 5/1/2019, 1,666 shares on 5/1/2020 and 1,667 on 5/1/2021
- F3663 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022
- F41,837 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022